CHUGAI PHARMACEUTICAL CO., LTD.

Home > CSR > Chugai's Approach to CSR > Initiatives and Performance

Initiatives and Performance

Below is a summary of the CSR activities the Chugai Group conducts in various fields for the benefit of stakeholders, centered on the supply of innovative medicines and services.

Initiatives and Performance in 2010

Items Main initiatives Main performance indicators in 2010
High ethical and moral standards
  • Fostering high ethical standards through training on the Chugai BCG, continuous efforts to build human rights awareness
  • Conducting CSR/BCG awareness survey of all employees and monitoring awareness of and conduct with respect to Chugai's social responsibility, Mission, Core Values and the BCG
  • Maintaining high animal welfare standards in accordance with international guidelines
  • Promoting compliance with the Pharmaceutical Affairs Law, fair competition codes, promotion codes, and other laws and regulations
  • BCG and Human Rights training attendees: 13,317 (includes repeat attendees; Chugai Group in Japan)
  • Awareness survey respondents: 6,006
  • In-house education and training for people who handle laboratory animals: 41 sessions attended by 623 people
  • State of ethical and legal compliance survey within the Sales Division: Responses received from 2,312 people
Patients and consumers
  • Pursuing the development and provision of innovative pharmaceuticals
  • Conducting activities to build awareness of disease in priority fields
  • Conducting support activities for patients
  • Providing support for researchers from Asia
  • Responding to inquiries and disclosing information
  • Approval of Actemra® in U.S.; removal of post-marketing all-patient surveillance approval condition for Actemra® (rheumatoid arthritis) and Avastin® in Japan
  • R&D expenses/sales: 14.4% (Chugai Group)
  • Special sponsorship of a cancer charity event: "Medicine and Humor" featuring rakugo storyteller Dansyun Tatekawa (Dec. 19 in Yokohama); participation in Relay For Life Japan 2010
  • Cumulative number of countries receiving free therapeutic drugs for treating children with lymphangioma: 69 (program in its 20th year)
  • Disease awareness activities and co-sponsored events held: 20
  • Customer inquiries answered by Chugai's Drug Information Center: 52,353 (includes telephone, e-mail and fax inquiries)
Shareholders and investors
  • Disclosing information in an unbiased and highly transparent manner
  • Holding frequent dialogues with investors in and outside Japan
  • Holding general meetings of shareholders and shareholder receptions
  • Realizing steady dividend payments
  • Briefings for the media and investors: 19
  • Responses made to individual requests for information, such as by securities analysts: 210
  • Institutional investors outside Japan visited in person by top executives: 74
  • General meeting of shareholders and shareholders' reception: 762 participants at the Royal Park Hotel in Tokyo on March 25, 2010
  • Return on equity (ROE): 9.4% (Chugai Group)
  • Dividend per share: ¥40 (annual)
Business partners
  • Continuously standardizing and optimizing purchasing processes to build fair, transparent relationships
  • Promoting purchasing that balances compliance, business efficiency and purchasing cost reduction
  • Clarified internal roles and responsibilities by restructuring purchasing processes and rules
  • Promoted fairness and transparency and catalogued indirect materials in the electronic purchasing system
  • Incorporated new competitive quotation mechanism into the purchasing system
Communities
  • Conducting welfare initiatives for the elderly and people with disabilities
  • Nurturing the next generation of individuals who will carry science and technology forward
  • Supporting employee volunteer activities
  • Contributing to communities where Chugai Group facilities and sites are located
  • Recipients of welfare vehicles to provide transportation for home welfare services: a total of 183 vehicles over 26 years (total of five vehicles to five organizations in 2010)
  • Video presentations given at Dr. Kitanomaru's Bio Pharmaceutical Laboratory exhibit: 41,072 (January to December, 2010)
  • Summer Biotech Lab for Kids at the Japan Science Foundation's Science Museum in Tokyo: 91 participants in lab, 449 at hands-on corner
  • Employees taking volunteer holiday: 2
  • Classes for the local community at Shizuoka Sangyo University: total 12 lectures
Employees
  • Fostering human assets who are competent in the global arena
  • Building a work environment that is motivating and fulfilling for every employee
  • Building sound labor-management relations
  • Creating safe, pleasant workplaces
  • Future Core Leaders Program, HR Reinforcement Basic Program, Functional Expertise Program and Self-Innovation Program
  • Number of employees taking childcare leave: 32
  • Users of wiwiw (an online tool that supports employees who return to work after taking childcare leave): 32 (cumulative total)
  • Percentage of employees with disabilities: 1.87%
  • Rate of lost-worktime injuries: 2.63
  • Accidents accompanied by lost worktime: 4 (Chugai Group in Japan)
  • Lost workdays resulting from occupational accidents: 14 (Chugai Group in Japan)
Environmental protection and occupational safety and health
  • Promoting global warming countermeasures
  • Pursuing resource conservation and waste reduction
  • Enhancing environmental awareness
  • Making environment-related contributions to local communities
  • Disclosing environmental information
  • Thoroughly managing chemical substances
  • CO2 emissions compared with 2003: Up 36% (Chugai Group in Japan)
  • Petroleum-based fuel usage: 10.6% (total for plants and research laboratories)
  • Ratio of hybrid sales vehicles: 37.0%
  • Volume of waste generated compared with 2003: 30.7% (Chugai Group in Japan)
  • Volume of landfilled waste compared with 2003: 18.8% (Chugai Group in Japan)
Making the Chugai BCG Part of Our DNA

Motoo Ueno, Representative Director, Deputy President, Corporate Social Responsibility

Business management that actively addresses underlying social issues and the expectations and requests of stakeholders is becoming increasingly important. The Chugai Group believes that delivering value to stakeholders by providing ethically sound and science-based innovative medicines is its social responsibility. To fulfill it, we are instilling and entrenching the Chugai Business Conduct Guidelines (Chugai BCG), a code of behavior that shows how we should provide value. Our goal is to make these guidelines part of our corporate DNA. We are conducting ongoing activities to create an organization in which every employee proactively and autonomously makes judgments and acts in accordance with shared values and standards.
Motoo Ueno,
Representative Director, Deputy President, Corporate Social Responsibility

  • Print
  • View in Japanese